Jennifer R. Brown - Publications, H-index & Citations

Jennifer R. Brown

dana-farber cancer institute

89H指数

1.2K论文数

4.4W被引数

收录论文 175

发表时间

Association between patient-reported symptoms and clinical outcomes in R/R CLL R/R CLL患者报告症状与临床结局之间的关联

Blood Advances

IF7.1

2026-09-17

OAAI

Timothy Victor; Gisoo Barnes; Mazyar Shadman; Nicole Lamanna; Constantine S. Tam; Luigi Qiu; Tommi Salmi; Frederick B. Barnes; Rasika Korde; Jennifer R. Brown

Preclinical and clinical efficacy of the HDAC6 inhibitor ricolinostat in combination with BCR pathway inhibitors in relapsed/refractory chronic lymphocytic leukemia HDAC6抑制剂rilocinostat与BCR通路抑制剂联合治疗复发/难治性慢性淋巴细胞白血病的临床前和临床疗效

Blood Cancer Journal

IF11.6

2026-07-13

OAAI

Stephen P. Martindale; Roberta Santos Azevedo; Drew A. Harrison; Bethany Tesar; Winnie Nguy; Miranda Stiegler; Valeria Ferre; Vanessa Rai; Yue Ren; Yinglu Zhou; Svitlana Tyekucheva; Stacey M. Fernandes; John-Hanson Machado; Binu Kandathilparambil Sasi; Aishath Naeem; Christopher J. Ott; Jennifer R. Brown

Safe Accelerated Venetoclax Escalation: a phase 1b study of obinutuzumab plus venetoclax with daily ramp-up in CLL 安全加速Venetoclax剂量递增：一项obinutuzumab联合Venetoclax每日递增剂量方案在CLL中的1b期研究

Blood Advances

IF7.1

2026-06-25

OAAI

Jennifer L. Crombie; Inhye E. Ahn; Yue Ren; Svitlana Tyekucheva; Celeste Carey; Mari Kniezewski; Samantha Normilus; Shantal Solomon; Josie Montegaard; Austin I. Kim; Reid W. Merryman; Philippe Armand; David C. Fisher; Jennifer R. Brown; Matthew S. Davids

A Comprehensive Review of the Role of Zanubrutinib for Patients with Chronic Lymphocytic Leukemia Bruton酪氨酸激酶抑制剂佐那布替尼在慢性淋巴细胞白血病治疗中的角色综述

Oncology and Therapy

IF3.2

2026-05-14

OAAI

Paolo Ghia; Jennifer R. Brown; Mazyar Shadman; Clemens-Martin Wendtner

Ibrutinib: 10 years and counting 伊布替尼：十年及以后

Blood

IF23.1

2026-04-09

PREAI

Jennifer R. Brown

Final phase 2 study results of acalabrutinib in treatment-naive and relapsed/refractory chronic lymphocytic leukemia Acalabrutinib在初治及复发/难治性慢性淋巴细胞白血病中的最终II期研究结果

Blood Advances

IF7.1

2026-04-02

OAAI

Richard R. Furman; William G. Wierda; Piers E.M. Patten; Jorge M. Chaves; Jennifer R. Brown; Talha Munir; Peter Martin; Farrukh T. Awan; Deborah M. Stephens; Paolo Ghia; Jacqueline C. Barrientos; Krish Patel; Jennifer A. Woyach; Marianne de Borja; Min-Hui Wang; Nitin Jain; Susan M. O’Brien; John C. Byrd

A phase I/II Study of Duvelisib plus Venetoclax in Patients with Relapsed/Refractory CLL/SLL or Richter Transformation 一项Duvelisib联合Venetoclax在复发/难治性CLL/SLL或Richter转化的患者中的I/II期研究

Blood Advances

IF7.1

2026-03-30

OAAI

Jennifer L. Crombie; Christine E. Ryan; Yue Ren; Svitlana Tyekucheva; Celeste Carey; Aaron Zou; Samantha Normilus; Josie Montegaard; Shruti Bhandari; Alvaro Alencar; Jacob D. Soumerai; Jon E. Arnason; Austin I. Kim; Erin M. Parry; Philippe Armand; David C. Fisher; Jennifer R. Brown; Matthew S. Davids

A renaissance in targeting the PI3K/AKT/mTOR pathway 靶向PI3K/AKT/mTOR途径的复兴

Nature Reviews Drug Discovery

IF101.8

2026-03-30

PREAI

Sarah E. Conduit; Neil Vasan; Jennifer R. Brown; Matthew W. D. Perry; Bart Vanhaesebroeck

First-line therapy for CLL: options abound CLL的一线治疗: 选择比比皆是

Nature Reviews Clinical Oncology

IF82.2

2026-02-12

PREAI

Jennifer R. Brown

Pirtobrutinib, a Highly Selective, Non-covalent (Reversible) BTKi in R/R Marginal Zone Lymphoma: Phase 1/2 BRUIN Study Pirtobrutinib，R/R边缘区淋巴瘤中的高选择性，非共价 (可逆) BTKi: 1/2期布鲁因研究

Blood Advances

IF7.1

2026-01-20

OAAI

Krish Patel; Julie Vose; Sunita D. Nasta; Jennifer R. Brown; Kami Maddocks; Jennifer Woyach; Nirav N. Shah; Bita Fakhri; Benoit Tessoulin; Shuo Ma; Deepa Jagadeesh; Ewa Lech-Maranda; Catherine C. Coombs; Manish R. Patel; Joanna M. Rhodes; Chaitra Ujjani; Marc S. Hoffmann; Chan Y. Cheah; Talha Munir; David Lewis

Novel PI3kδ inhibitor roginolisib synergizes with venetoclax in hematologic malignancies Sasi, B.K.; Tarantelli, C.; Martindale, S.; Civanelli, E.; Cannas, E.; Sartori, G.; Arribas, A.J.; Fernandes, S.M.; Shupe, S.J.; Machado, J.H.; 等. 新型PI3kδ抑制剂roginolisib与venetoclax在血液系统恶性肿瘤中具有协同作用。Haematologica 2025. [Google Scholar] [CrossRef] [PubMed]

HAEMATOLOGICA

IF7.9

2025-12-01

OAAI

Sasi, Binu Kandathilparambil; Tarantelli, Chiara; Martindale, Stephen; Civanelli, Elisa; Cannas, Eleonora; Sartori, Giulio; Arribas, Alberto J.; Fernandes, Stacey M.; Shupe, Samantha J.; Machado, John-Hanson; Tyekucheva, Svitlana; Ren, Yue; Lahn, Michael; van der Veen, Lars; Di Conza, Giusy; Bertoni, Francesco; Brown, Jennifer R.

Central Nervous System Involvement in CLL: An International Retrospective Study by ERIC, the European Research Initiative on CLL 慢性淋巴细胞白血病中中枢神经系统受累：ERIC（欧洲慢性淋巴细胞白血病研究倡议）国际回顾性研究

Blood Advances

IF7.1

2025-10-28

OAAI

Thomas Chatzikonstantinou; Mariia Mikhaleva; Christian Brieghel; Christine Papangelou; Eva Minga; Celso Arrais-Rodrigues; Sotiria Besikli-Dimou; Amalia Cerutti; Michael Doubek; Lisbeth Enggaard; Blanca Espinet; Blanca Ferrer-Lores; Jose Antonio Garcia Vela; Massimo Gentile; Eva Gimeno Vázquez; Odit Gutwein; Yair Herishanu; Paula Jablonowska-Babij; Ozren Jaksic; Par Josefsson; Elzbieta Kalicińska; Maria Kislova; Enrico Lista; Ioannis Kotsianidis; Juan Marquet; Enrica Antonia Martino; Ciaran McAuley; Maria José Mela Osorio; Riccardo Moia; Claudia Mosquera; Eugene Nikitin; Miguel Arturo Pavlovsky; Verena Pfister; Emine Merve Savaş; Lydia Scarfò; Matjaz Sever; Lev Shvidel; Martin Simkovic; Niki Stavroyianni; Persefoni Talimtzi; Antigoni Tranidou; Andrea Visentin; Georgios Vrachiolias; Ewa Wasik-Szczepanek; Tomasz Wróbel; Münci Yağcı; Alessandro Cellini; Anastasia Chatzidimitriou; Gianluca Gaidano; Mary Ann Anderson; Matthew S. Davids; Jennifer R. Brown; Carsten U. Niemann; Kostas Stamatopoulos; Paolo Ghia; Inhye E. Ahn; Maya Koren-Michowitz

Genomic Determinants of Response and Resistance to Pirtobrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia Pirtobrutinib对复发/难治性慢性淋巴细胞白血病的反应和耐药性的基因组决定因素

Blood

IF23.1

2025-10-10

OAAI

Jennifer R. Brown; Bastien Nguyen; Sai Prasad Desikan; Helen Won; Shady I. Tantawy; Samuel C. McNeely; Narasimha Marella; Hetal S. Randeria; Lauren M. Hanson; Andrew Parker; Salomé Calado Botelho; Jennifer A. Woyach; Krish Patel; Constantine S. Tam; Toby A. Eyre; Chan Y. Cheah; Nirav N. Shah; Paolo Ghia; Wojciech Jurczak; Minna Balbas; Binoj Nair; Paolo Abada; Chunxiao Wang; Denise Wang; Lindsey E. Roeker; Varsha Gandhi; William G. Wierda

Comprehensive comparison of enzymatic and bisulfite DNA methylation analysis in clinically relevant samples 临床相关样本中酶法和亚硫酸氢盐DNA甲基化分析的全面比较

Clinical Epigenetics

IF4.4

2025-10-05

OAAI

Barrett Nuttall; Daniel L. Karl; Kathleen Burke; Megan Callahan; Kerrin Mendler; Pablo Cingolani; Steven Criscione; Serhiy Naumenko; Elena Bibikova; Veerendra Munugalavadla; John C. Byrd; Richard R. Furman; Jennifer R. Brown; Andrew Mortlock; Brian A. Dougherty; J. Carl Barrett; Maurizio Scaltriti; James Hadfield

Resistance to Bruton Tyrosine Kinase Inhibitors 对Bruton酪氨酸激酶抑制剂的耐药性

HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

IF2.7

2025-10-01

PREAI

Brown, Jennifer R.

The Rapidly Evolving Landscape of the Biology and Therapy of Chronic Lymphocytic Leukemia 慢性淋巴细胞白血病生物学和治疗领域的快速发展态势

HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

IF2.7

2025-10-01

PREAI

Brown, Jennifer R.; Davids, Matthew S.

Favorable outcomes of restrictive treatment indications in chronic lymphocytic leukemia: a retrospective analysis of Brazilian Registry of CLL 慢性淋巴细胞白血病限制性治疗指征的有利结局：一项巴西CLL登记研究的回顾性分析

The Lancet Regional Health - Americas

IF0

2025-09-24

PREAI

Fernanda de Morais Marques; Verena Pfister; Flavia Parra; Leila Perobelli; Valeria Buccheri; Mihoko Yamamoto; Rodrigo Santucci; Sergio Costa Fortier; Vinicius Campos de Molla; Maura Rosane Valerio Ikoma-Colturato; Glaciano Ribeiro; Nelson Hamerschlak; Abel Costa; Laura Maria Fogliatto; Vera Lucia de Piratininga Figueiredo; Talita Silveira; Marcelo Pitombeira de Lacerda; Matheus Vescovi Gonçalves; Carlos Sérgio Chiattone; Jennifer R. Brown; Celso Arrais-Rodrigues

Zanubrutinib in the treatment of patients with del(17p) and/or TP53 CLL/SLL: analysis across clinical studies zanubrutinib在del(17p)和/或TP53 CLL/SLL患者治疗中的应用：临床研究分析

Blood Advances

IF7.1

2025-08-22

OAAI

Constantine S. Tam; Mary Ann Anderson; Martin Šimkovič; Paolo Ghia; Ian W. Flinn; Kamel Laribi; Stephen Opat; Gavin Cull; Talha Munir; Anders Österborg; Alessandra Tedeschi; Megan Wang; Andy Szeto; Heather Allewelt; Tommi Salmi; Jessica Li; Linlin Xu; Ken Wu; Remus Vezan; Mazyar Shadman; Jennifer R. Brown

Notch pathway inhibition with crenigacestat (LY3039478) in a phase I first-in-human clinical trial for patients with relapsed or refractory non-Hodgkin lymphoma and B-cell chronic lymphocytic leukemia 使用crenigacestat（LY3039478）抑制Notch通路在复发或难治性非霍奇金淋巴瘤和B细胞慢性淋巴细胞白血病患者中的I期首次人体临床试验

Therapeutic Advances in Drug Safety

IF3.4

2025-07-31

OAAI

Jean-Marie Michot; Zsofia Balogh; Jennifer R. Brown; Vincent Ribrag; Antoine Hollebecque; Rastislav Bahleda; Cyril Quivoron; Samy Ammari; Jean-Yves Scoazec; Karim A. Benhadji; Christophe Massard

Rare germline variant in NFATC4 associated with familial CLL NFATC4基因中的罕见胚系变异与家族性慢性淋巴细胞白血病相关

Leukemia

IF13.4

2025-07-28

PREAI

Gilad Itchaki; Harrison Bai; Grace Tiao; Reina Improgo; Ben E. Oppenheimer; Siddha Kasar; Bethany Tesar; Stacey M. Fernandes; Nathalie Pochet; John-Hanson Machado; Emily M. Thrash; Arnold S. Freedman; Gad Getz; Jennifer R. Brown

研究方向